ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,882,000 | -40.9% | 100,000 | -50.0% | 0.01% | -75.8% |
Q4 2022 | $3,184,000 | +11.2% | 200,000 | +14.3% | 0.03% | +32.0% |
Q3 2022 | $2,863,000 | -27.4% | 175,000 | -37.5% | 0.02% | -16.7% |
Q2 2022 | $3,945,000 | +715.1% | 280,000 | +1300.0% | 0.03% | +328.6% |
Q1 2022 | $484,000 | -53.9% | 20,000 | -55.6% | 0.01% | -36.4% |
Q4 2021 | $1,050,000 | -84.1% | 45,000 | -88.7% | 0.01% | -87.8% |
Q3 2021 | $6,594,000 | +350.7% | 397,000 | +561.7% | 0.09% | +400.0% |
Q2 2021 | $1,463,000 | +89.0% | 60,000 | +100.0% | 0.02% | +80.0% |
Q1 2021 | $774,000 | -37.5% | 30,000 | 0.0% | 0.01% | -44.4% |
Q3 2020 | $1,238,000 | +208.7% | 30,000 | +100.0% | 0.02% | +100.0% |
Q2 2019 | $401,000 | -0.5% | 15,000 | 0.0% | 0.01% | +80.0% |
Q1 2019 | $403,000 | +65.8% | 15,000 | 0.0% | 0.01% | +66.7% |
Q4 2018 | $243,000 | -70.7% | 15,000 | -62.5% | 0.00% | -70.0% |
Q3 2018 | $830,000 | +35.8% | 40,000 | 0.0% | 0.01% | +11.1% |
Q2 2018 | $611,000 | -77.8% | 40,000 | -50.0% | 0.01% | -75.7% |
Q1 2017 | $2,750,000 | – | 80,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |